Cellgenemedix owns exclusive genomic test technology and tailor-made stem cell therapy, where we treat patients in Korea, Kazakhstan and plan to do so in Mexico as well.
Commercialization of cell bank and cell therapy
We see more and more people store their cells in cell banks when they are healthy or when their children are born and use the cells when they need (i.e. when they are sick, need to prevent disease, or need in order to improve quality of life). The purpose of cell banking is to provide stem cells and immune cells for the prevention of diseases which are predicted to come and also for the treatment of diseases which are found at time of our testing. Human cells, tissues, and cellular and tissue-based products (HCT/Ps) consist of human cells or tissues intended for implantation, transplantation, infusion or transfer into a human recipient. The Food and Drug Administration regulates a cellular therapy product solely as an HCT/P (i.e. “361 product”) if it meets all the following criteria in 21 CFR 1271.10(a)
Two types of cells, stem cells and immune cells, protect us from the environmental and genetic diseases; cancers and infections.
- Stem cells ((autologous or allogenic, from donor or newborn baby’s umbilical cord/placenta/amniotic fluid, etc) are the mother of all of human cells and functions to regenerate our body.
- Many adult stem cells, namely mesenchymal stem cells (MSCs) and neural stem cells (NSCs), have intrinsic tumour-tropic properties, which makes them a novel targeted cellular delivery vehicle for anti-cancer agents.
- Stem cells, along with their ability to home to the primary tumour mass, can efficiently track micro-metastatic lesions and can be engineered to express or secrete a range of anti-cancer agents.
- Cancer stem cells (CSCs) or tumour-initiating cells (TICs): these are new targets for immune intervention for both solid and haematologic malignancies
- Stem-cell based therapeutic platforms: these include haematopoietic stem cells, reprogrammed pluripotent stem cells, stem cell-like memory T-cells and tumour-derived stem cells.
- Majority of haematopoietic stem cells are present in bone marrow
- When there is a demand from body for regeneration, such as trauma, surgery, loss of tissue due to diseases, stem cells are made in big numbers, after which they migrate to damaged tissue and with cooperation of stem cells in local tissue, they regenerate tissues.
2. Immune cells are the primary defense mechanism against diseases and hostile environment, such as infection and cancer (like “father”).
- NK cells, NK/T cells, CIK cells, dendritic cells, and CAR-T cells, gene modified dendritic cells, gene modified NK cells.
- number and activity of immune cells decrease as we age
- Adoptive T-cell therapy or adoptive cell transfer therapy : this is designed to enrich tumor infiltration lymphocytes by multiplying T-cells removed directly from the patient’s tumor microenvironment. These are analyzed based on the receptors’ specificity or to determine which receptors are more specific to the tumor. These cells are then administered to the patient after being generated in greater numbers to initiate a massive anti-tumor immune response.
3. Stem cells in Regenerative medicine and Cosmetics
- Allogenic stem cell use in cosmetics is primarily using stem cells of human or animal origin for the mass production of stem cell-derived products.
- Most cell skin care products contain plant stem cells, and more specifically, stem cell extracts.
- We have experience in supplying animal stem cells, specifically stem cell condition media, to cosmetic companies and with our decades of experience are open to more business collaborations in this genre. We ave experience in allogenic whole-stem cell use for cosmetic applications especially adipose stem cells (ASC). Additionally, the ASC secretome (conditioned media or “exosomes”) has demonstrated similar effectiveness in regenerative and copsmetic medicine applications.
- We believe that ASCs have more applications in cosmetic use compared to PRP (platelet rich plasma) due to the fact that it is more effective in rejuvenation and more applicable to allogenic (to everyone/other people) rather than autologous (to self).
- The concern is that stem cell may have potential risks, specifically various immune reactions or tumorigenicity (unspecific differentiation), especially when using whole cells, especially when certain sub-types such as embryonic and induced pluripotent stem cells are used.
- However, many research papers have suggested that very few adverse events can be related directly to the ASC therapy, events were rather related to the harvesting of adipose tissue, trauma associated with injection, or the nature of the underlying condition being treated. Furthermore, there was no clear evidence of a clinical immune response, even in allogeneic ASC treatment.
Stem cell-derived extracellular vesicles (EVs) offer alternative approaches to stem cell-based therapy for regenerative medicine as secreted EVs during stem cell differentiation into white adipocytes or beige adipocytes can promote cell reprogramming.
We have a 10-year expertise in cord blood banking (in Korea) and research experience related to both pluripotent and mesenchymal stem cells which we aim to apply to cosmetics and plastics.
All our cells are collected and regulated per the newest guidelines for cell therapy
We have the required facility to work with and distribute these cells in Asia and parts of the Americas.
Refer to our nutrition and cosmetics section for information on our research in that regard.
#Not currently distributed in United States. Please inquire below.